Login to Your Account



Pharma: Other News To Note


Wednesday, September 18, 2013
• Teva Pharmaceutical Industries Ltd., of Petach Tikva, Israel, said the FDA approved Treanda (bendamustine HCl) injection, a new formulation of currently approved Treanda, indicated for use in patients with indolent B-cell non-Hodgkins’ lymphoma that has progressed during or within six months of treatment with Rituxan (rituximab, Biogen Idec Inc. and Roche AG) or a Rituxan-containing regimen and in patients with chronic lymphocytic leukemia. Teva acquired Treanda through its 2011 buyout of Cephalon Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription